Do you know what DOG ESSENTIALS you are missing out? Find out now!
Zack Keithy, our author, is a certified veterinarian technician (UC Blue Ash) for over 6 years (contact him here). The articles written here are based on his expertise and experience, combined with a review by our expert vet reviewers including Dr M. Tarantino. Learn more about us here.
An investigational cannabidiol (CBD) and tetrahydrocannabinol (THC) oral solution for dogs with bone cancer pain is now eligible to pursue conditional approval from the FDA. The drug, called CannEpil, is still not approved or conditionally approved.
The FDA’s Center for Veterinary Medicine determined that CannEpil’s proposed use qualifies as a “minor use” under its Minor Use and Minor Species (MUMS) program. The developers, Endovia Health Sciences and Lupvindol BioSciences, announced the decision on October 5, 2026.
The agency also determined the product will keep its minor-use status through approval of its New Animal Drug Application. The MUMS program exists to encourage drug development for uncommon conditions that affect relatively small populations.
Conditional approval is meant to get eligible therapies to patients sooner. The drug must meet FDA requirements for safety and manufacturing and show a reasonable expectation of effectiveness.
That is a lower bar than the substantial evidence required for full approval. The sponsor can then legally market the drug while it collects the remaining effectiveness data.
Conditional approval lasts one year and can be renewed annually for up to four more years. The companies are scheduled to meet with the FDA on November 19, 2026 to align on the studies and manufacturing requirements needed.
They are also sourcing US-based manufacturing. If approvals come through, a veterinary launch is possible in 2027, though the companies say that depends on FDA review and manufacturing readiness.
“We are not waiting to begin preparing for commercialization,” said Brady Cobb, Endovia’s interim chief executive officer. He described the program as a way to address an unmet need for dogs suffering from cancer-related pain.
The companies say the veterinary program is part of a broader effort to develop cannabinoid-based therapeutics through federal pathways, with possible future human applications.
My thoughts:
The key word in this story is “eligible.” The FDA hasn’t approved anything. It has agreed that this use qualifies for a route that could eventually get the drug to market sooner.
Most of the forward-looking claims, including the 2027 launch and the “unmet need” framing, come from the developers’ own announcement. They’re plans, not results.
For owners of dogs with bone cancer, nothing changes today, because the drug isn’t available. But it’s a notable step for a condition where pain control is a major part of care.
Source: dvm360, reporting by Justin Louis, based on an October 5, 2026 announcement from Endovia Health Sciences and Lupvindol BioSciences
